Figure 2

Value of p53 mutations in predicting DFS benefit from adding docetaxel to control anthracycline-based therapy. (a) Wild-type p53 versus mutant p53 protein. (b) p53 wild-type versus missense mutant versus truncated mutant. Treatment comparisons were made between (i) anthracycline control arms (A+AC) and sequential docetaxel (A-T); (ii) anthracycline control arms (A+AC) and concurrent docetaxel (AT); and (iii) anthracycline control arms (A+AC) and combined docetaxel arms (A-T+AT). A, doxorubicin; C, cyclophosphamide; DFS, disease-free survival; T, docetaxel.